# Powering Progress: Fusion, Solar, and Health Breakthroughs! Newsy: The Bright Side Published: 2026-09-08T13:30:00.375Z Source: https://newsyai.com/edition/4ebd9b7d-0304-43a0-8e52-16845692cadb Archive: https://newsyai.com/newsy/dddcdfd1-ba63-4579-8b9c-883acd9f1fa5.md --- **Engineering Abundance: Record Fusion Funding Surge, Solar Hits 10% Global Electricity, New Gene Therapies for Hearing Loss & Rare Diseases, and Bold Conservation Investments!** **Good Morning, Optimist! 🌅 September 8, 2026** Human ingenuity is accelerating on multiple fronts, turning ambitious visions into measurable milestones. Fresh record investments in fusion, solar power claiming a bigger slice of the global grid than ever, expanded access to life-changing gene therapies, and major new funding for species recovery all point to compounding progress. These wins reinforce one another: cleaner energy supports healthier communities and thriving ecosystems, while scientific breakthroughs inspire further collaboration. The momentum builds steadily toward greater abundance. ## Clean Energy: Record $4.48 Billion in Fusion Funding; DOE Roadmap Charts Path to Mid-2030s Deployment; Solar Reaches 10% of Global Electricity The fusion sector attracted a record $4.48 billion in private investment over the 12 months ending July 2026—up 69% from the prior year—bringing cumulative funding since 2021 to $14.24 billion across 56 companies. Major rounds included support for companies like Proxima Fusion and preparations for public listings by TAE Technologies and General Fusion, signaling growing confidence from institutional and corporate backers, including AI-driven demand for reliable power.[[1]](https://www.fusionindustryassociation.org/fusion-industry-attracts-record-annual-funding-of-4-48bn-raising-total-to-14-24bn/)[[2]](https://www.reuters.com/business/energy/global-fusion-energy-annual-investments-hit-record-nearly-45-billion-2026-07-13/) The U.S. Department of Energy released its finalized Fusion Science & Technology Roadmap in June 2026, outlining a coordinated national strategy with ten key actions under a “Build-Innovate-Grow” framework. It emphasizes public-private partnerships, supply chain development, and cost-competitive pathways to pilot plants and commercial power in the mid-2030s, building on over $10 billion in private capital already deployed.[[3]](https://www.energy.gov/articles/energy-department-releases-finalized-fusion-science-and-technology-roadmap-accelerate) On the solar front, a new Ember analysis shows solar supplied a record 10% of global electricity generation in the first half of 2026—nearly doubling its share from 5.6% in H1 2023. Batteries are unlocking greater utilization, with 2026 deployments expected to shift over a third of new daily solar output to non-sunny hours. The global solar fleet surpassed 3 TW earlier this year after record 664 GW installed in 2025.[[4]](https://ember-energy.org/latest-insights/batteries-have-unlocked-the-era-of-anytime-solar/)[[5]](https://www.solarpowereurope.org/press-releases/new-report-global-solar-market-hits-new-record-of-664-gw-installation-in-2025-as-global-solar-fleet-passes-3-tw) These developments highlight how capital, policy alignment, and technology are scaling clean energy rapidly. ## Gene Therapies: First Approvals for Genetic Hearing Loss and Glycogen Storage Disease; Expanded Options for Rare Conditions The FDA approved Otarmeni, the first-ever dual AAV vector-based gene therapy for severe-to-profound hearing loss linked to biallelic OTOF gene variants. This one-time treatment offers hope for restoring hearing in pediatric and adult patients, following swift review under the Commissioner’s National Priority Voucher program.[[6]](https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher) Genglycos received accelerated approval as the first therapy for glycogen storage disease type Ia (GSDIa) in patients aged 8 and older. The one-time AAV8-based gene therapy targets the root cause by delivering a functional G6PC gene to the liver, significantly reducing the need for daily cornstarch intake and stabilizing blood sugar.[[7]](https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia) Additional momentum includes Tudriqev, an oncolytic viral immunotherapy for treatment-resistant advanced melanoma, and Waskyra, the first cell-based gene therapy for Wiskott-Aldrich syndrome.[[8]](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma)[[9]](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome) These approvals expand precise genetic medicines to new patient groups, delivering targeted, potentially transformative options where few existed. ## Conservation: UK’s Record £90 Million Species Recovery Investment; CITES Protections Advance; Midwest Recovery Champions and Global Reintroductions Succeed The UK government announced its largest-ever investment in threatened species recovery—£60 million over three years for the Species Recovery Programme (more than doubling prior funding) plus £30 million for national forest estate work. This supports over 600 species, with recent wins including the first wild-hatched red-billed chough in Kent in over 200 years, black grouse reintroductions, and the large marsh grasshopper’s return after 85 years.[[10]](https://www.gov.uk/government/news/largest-ever-government-investment-in-threatened-species-recovery) CITES CoP20 delivered new protections for dozens of species, including sharks, rays, okapi, and various reptiles and primates, strengthening international trade safeguards.[[11]](https://awionline.org/awi-quarterly/spring-2026/cites-cop20-concludes-with-conservation-successes/) In the U.S., the Fish and Wildlife Service named 2025 Midwest Recovery Champions, recognizing efforts that boosted Great Lakes piping plover pairs from 13 in 1984 to 88 in 2025, sustained robust wolf populations with low conflict, and advanced Kirtland’s warbler recovery.[[12]](https://www.fws.gov/story/2026-09/2025-midwest-recovery-champions) Globally, initiatives like the Colossal Foundation and Re:Wild Species Reintroduction Fund are supporting projects such as banteng reintroductions in Cambodia, brown howler monkeys in Brazil, and sihek (Guam kingfisher) releases yielding the first wild eggs in a generation.[[13]](https://www.greenmatters.com/big-impact/nobody-told-these-seven-species-they-were-supposed-to-stay-gone) These efforts prove that sustained, community-centered action and strategic funding deliver tangible biodiversity gains. ## Momentum Toward Greater Abundance From record fusion funding and the DOE’s clear commercialization roadmap to solar’s 10% global electricity milestone, fresh gene therapy approvals reaching new conditions and age groups, and landmark investments in species recovery across the UK, U.S., and beyond, today’s updates underscore accelerating, interconnected progress. Clean energy powers healthier lives; medical advances reduce suffering; restored ecosystems build resilience. We measure success in billions invested, percentages gained, patients treated, and populations rebounding—the trajectory points to engineered abundance. > “The best way to predict the future is to create it.” – Inspired by Peter Diamandis Rise ready—the momentum is building! 🌍✨ **Sources** (for easy verification): - Fusion funding record & companies: Fusion Industry Association / Reuters (July 2026) - DOE Fusion Roadmap: U.S. Department of Energy (June 2026) - Solar 10% global share & battery impact: Ember (Sept 2026) - Global solar installations & 3 TW fleet: SolarPower Europe (June 2026) - Otarmeni hearing loss approval: FDA (2026) - Genglycos GSDIa approval: FDA (Aug 2026) - Tudriqev & Waskyra approvals: FDA (2026) - UK Species Recovery Programme: GOV.UK (April 2026) - CITES CoP20: Animal Welfare Institute (2026) - Midwest Recovery Champions: U.S. Fish & Wildlife Service (Sept 2026) - Reintroduction Fund projects: Green Matters (Aug 2026) Stay curious and optimistic—more good news tomorrow!